{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:23:41Z","timestamp":1782516221298,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ovarian cancer is a devastating gynecological malignancy and frequently presents as an advanced carcinoma with disseminated peritoneum metastasis. Acacetin exerts anti-cancerous effects in several carcinomas. Here, we sought to investigate acacetin function in ovarian cancer malignancy triggered by peritoneal mesothelial cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Peritoneal mesothelial cells were treated with acacetin, and then the conditioned medium was collected to treat ovarian cancer cells. Then, cell proliferation was analyzed by MTT assay. Transwell analysis was conducted to evaluate cell invasion. Protein expression was determined by western blotting. ELISA and qRT-PCR were applied to analyze inflammatory cytokine levels. The underlying mechanism was also explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Acacetin suppressed cell proliferation and invasion, but enhanced cell apoptosis. Furthermore, mesothelial cell-evoked malignant characteristics were inhibited when mesothelial cells were pre-treated with acacetin via restraining cell proliferation and invasion, concomitant with decreases in proliferation-related PCNA, MMP-2 and MMP-9 levels. Simultaneously, acacetin reduced mesothelial cell-induced transcripts and production of pro-inflammatory cytokine IL-6 and IL-8 in ovarian cancer cells. Mechanically, acacetin decreased lysophosphatidic acid (LPA) release from mesothelial cells, and subsequent activation of receptor for advanced glycation end-products (RAGE)-PI3K\/AKT signaling in ovarian cancer cells. Notably, exogenous LPA restored the above pathway, and offset the efficacy of acacetin against mesothelial cell-evoked malignancy in ovarian cancer cells, including cell proliferation, invasion and inflammatory cytokine production.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Acacetin may not only engender direct inhibition of ovarian cancer cell malignancy, but also antagonize mesothelial cell-evoked malignancy by blocking LPA release-activated RAGE-PI3K\/AKT signaling. Thus, these findings provide supporting evidence for a promising therapeutic agent against ovarian cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Graphical Abstract<\/jats:title><\/jats:sec>","DOI":"10.1186\/s11658-021-00296-3","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T11:11:23Z","timestamp":1639048283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Amelioration of human peritoneal mesothelial cell co-culture-evoked malignant potential of ovarian cancer cells by acacetin involves LPA release-activated RAGE-PI3K\/AKT signaling"],"prefix":"10.1186","volume":"26","author":[{"given":"Meng","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"296_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"296_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"296_CR3","first-page":"2475","volume":"40","author":"K Saika","year":"2013","unstructured":"Saika K, Sobue T. Cancer statistics in the world. Gan To Kagaku Ryoho. 2013;40:2475\u201380.","journal-title":"Gan To Kagaku Ryoho"},{"key":"296_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"296_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1369\/0022155417742897","volume":"66","author":"J van Baal","year":"2018","unstructured":"van Baal J, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ, et al. Development of peritoneal carcinomatosis in epithelial Ovarian cancer: a review. J Histochem Cytochem. 2018;66:67\u201383.","journal-title":"J Histochem Cytochem"},{"key":"296_CR6","doi-asserted-by":"crossref","unstructured":"Aziz M, Agarwal K, Dasari S, Mitra AAK. Productive cross-talk with the microenvironment: a critical step in Ovarian cancer metastasis. Cancers (Basel). 2019;11.","DOI":"10.3390\/cancers11101608"},{"key":"296_CR7","doi-asserted-by":"crossref","unstructured":"Dasari S, Fang Y, Mitra AK. Cancer associated fibroblasts: naughty neighbors that drive Ovarian cancer progression. Cancers (Basel). 2018;10.","DOI":"10.3390\/cancers10110406"},{"key":"296_CR8","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1172\/JCI74778","volume":"124","author":"HA Kenny","year":"2014","unstructured":"Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014;124:4614\u201328.","journal-title":"J Clin Invest"},{"key":"296_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/089686080602600207","volume":"26","author":"S Yung","year":"2006","unstructured":"Yung S, Li FK, Chan TM. Peritoneal mesothelial cell culture and biology. Perit Dial Int. 2006;26:162\u201373.","journal-title":"Perit Dial Int"},{"key":"296_CR10","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-05-1292","volume":"66","author":"J Ren","year":"2006","unstructured":"Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 2006;66:3006\u201314.","journal-title":"Cancer Res"},{"key":"296_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biocel.2018.03.011","volume":"98","author":"M Pakula","year":"2018","unstructured":"Pakula M, Mikula-Pietrasik J, Stryczynski L, Uruski P, Szubert S, Moszynski R, et al. Mitochondria-related oxidative stress contributes to ovarian cancer-promoting activity of mesothelial cells subjected to malignant ascites. Int J Biochem Cell Biol. 2018;98:82\u20138.","journal-title":"Int J Biochem Cell Biol"},{"key":"296_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.nut.2016.03.020","volume":"32","author":"S Venturelli","year":"2016","unstructured":"Venturelli S, Burkard M, Biendl M, Lauer UM, Frank J, Busch C. Prenylated chalcones and flavonoids for the prevention and treatment of cancer. Nutrition. 2016;32:1171\u20138.","journal-title":"Nutrition."},{"key":"296_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11010-009-0229-8","volume":"333","author":"KH Shen","year":"2010","unstructured":"Shen KH, Hung SH, Yin LT, Huang CS, Chao CH, Liu CL, et al. Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. Mol Cell Biochem. 2010;333:279\u201391.","journal-title":"Mol Cell Biochem"},{"key":"296_CR14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s12272-017-0991-1","volume":"41","author":"LC Sun","year":"2018","unstructured":"Sun LC, Zhang HB, Gu CD, Guo SD, Li G, Lian R, et al. Protective effect of acacetin on sepsis-induced acute lung injury via its anti-inflammatory and antioxidative activity. Arch Pharm Res. 2018;41:1199\u2013210.","journal-title":"Arch Pharm Res"},{"key":"296_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4103\/1673-5374.247465","volume":"14","author":"J Bu","year":"2019","unstructured":"Bu J, Shi S, Wang HQ, Niu XS, Zhao ZF, Wu WD, et al. Acacetin protects against cerebral ischemia-reperfusion injury via the NLRP3 signaling pathway. Neural Regen Res. 2019;14:605\u201312.","journal-title":"Neural Regen Res"},{"key":"296_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/carcin\/bgt266","volume":"35","author":"SK Jung","year":"2014","unstructured":"Jung SK, Kim JE, Lee SY, Lee MH, Byun S, Kim YA, et al. The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer. Carcinogenesis. 2014;35:123\u201330.","journal-title":"Carcinogenesis"},{"key":"296_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1016-8478(23)10760-6","volume":"24","author":"HY Shim","year":"2007","unstructured":"Shim HY, Park JH, Paik HD, Nah SY, Kim DS, Han YS. Acacetin-induced apoptosis of human breast cancer MCF-7 cells involves caspase cascade, mitochondria-mediated death signaling and SAPK\/JNK1\/2-c-Jun activation. Mol Cells. 2007;24:95\u2013104.","journal-title":"Mol Cells"},{"key":"296_CR18","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/ijc.25938","volume":"129","author":"JT Thaiparambil","year":"2011","unstructured":"Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer. 2011;129:2744\u201355.","journal-title":"Int J Cancer"},{"key":"296_CR19","doi-asserted-by":"publisher","first-page":"9653","DOI":"10.1074\/jbc.M306662200","volume":"279","author":"X Fang","year":"2004","unstructured":"Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004;279:9653\u201361.","journal-title":"J Biol Chem"},{"key":"296_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1593\/neo.06658","volume":"9","author":"NA Said","year":"2007","unstructured":"Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia. 2007;9:23\u201335.","journal-title":"Neoplasia"},{"key":"296_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","volume":"7","author":"DS Tan","year":"2006","unstructured":"Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7:925\u201334.","journal-title":"Lancet Oncol"},{"key":"296_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/dc.20133","volume":"31","author":"B Davidson","year":"2004","unstructured":"Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol. 2004;31:246\u201354.","journal-title":"Diagn Cytopathol"},{"key":"296_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.canlet.2014.09.041","volume":"355","author":"J Mikula-Pietrasik","year":"2014","unstructured":"Mikula-Pietrasik J, Sosinska P, Kucinska M, Murias M, Maksin K, Malinska A, et al. Peritoneal mesothelium promotes the progression of ovarian cancer cells in vitro and in a mice xenograft model in vivo. Cancer Lett. 2014;355:310\u20135.","journal-title":"Cancer Lett"},{"key":"296_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1479-5876-2-23","volume":"2","author":"RS Freedman","year":"2004","unstructured":"Freedman RS, Deavers M, Liu J, Wang E. Peritoneal inflammation: a microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med. 2004;2:23.","journal-title":"J Transl Med"},{"key":"296_CR25","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1593\/neo.08672","volume":"10","author":"NA Said","year":"2008","unstructured":"Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia. 2008;10:1092\u2013104.","journal-title":"Neoplasia"},{"key":"296_CR26","doi-asserted-by":"crossref","unstructured":"Rodrigues ISS, Martins-Filho A, Micheli DC, Lima CA, Tavares-Murta BM, Murta EFC, et al. IL-6 and IL-8 as Prognostic factors in peritoneal fluid of ovarian cancer. immunol invest. 2019:1\u201312.","DOI":"10.1080\/08820139.2019.1691222"},{"key":"296_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cyto.2009.03.013","volume":"46","author":"J Yang","year":"2009","unstructured":"Yang J, Wang Y, Gao Y, Shao J, Zhang XJ, Yao Z. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine. 2009;46:382\u201391.","journal-title":"Cytokine"},{"key":"296_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s11658-016-0003-3","volume":"21","author":"S Arabzadeh","year":"2016","unstructured":"Arabzadeh S, Hossein G, Salehi-Dulabi Z, Zarnani AH. WNT5A-ROR2 is induced by inflammatory mediators and is involved in the migration of human ovarian cancer cell line SKOV-3. Cell Mol Biol Lett. 2016;21:9.","journal-title":"Cell Mol Biol Lett"},{"key":"296_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13277-010-0123-8","volume":"32","author":"I Sedlakova","year":"2011","unstructured":"Sedlakova I, Vavrova J, Tosner J, Hanousek L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol. 2011;32:311\u20136.","journal-title":"Tumour Biol"},{"key":"296_CR30","doi-asserted-by":"crossref","unstructured":"Xu Y. Targeting lysophosphatidic acid in cancer: the issues in moving from bench to bedside. Cancers (Basel). 2019;11.","DOI":"10.3390\/cancers11101523"},{"key":"296_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3233\/CBM-160674","volume":"18","author":"F Rahimi","year":"2017","unstructured":"Rahimi F, Karimi J, Goodarzi MT, Saidijam M, Khodadadi I, Razavi AN, et al. Overexpression of receptor for advanced glycation end products (RAGE) in ovarian cancer. Cancer Biomark. 2017;18:61\u20138.","journal-title":"Cancer Biomark"},{"key":"296_CR32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1084\/jem.20120873","volume":"209","author":"V Rai","year":"2012","unstructured":"Rai V, Toure F, Chitayat S, Pei R, Song F, Li Q, et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med. 2012;209:2339\u201350.","journal-title":"J Exp Med"},{"key":"296_CR33","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jfda.2019.07.001","volume":"27","author":"CY Lan","year":"2019","unstructured":"Lan CY, Chen SY, Kuo CW, Lu CC, Yen GC. Quercetin facilitates cell death and chemosensitivity through RAGE\/PI3K\/AKT\/mTOR axis in human pancreatic cancer cells. J Food Drug Anal. 2019;27:887\u201396.","journal-title":"J Food Drug Anal"},{"key":"296_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360.","journal-title":"Semin Cancer Biol"},{"key":"296_CR35","doi-asserted-by":"publisher","first-page":"12642","DOI":"10.1038\/srep12642","volume":"5","author":"JG Lee","year":"2015","unstructured":"Lee JG, Ahn JH, Jin Kim T, Ho Lee J, Choi JH. Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin beta4 and Akt signals. Sci Rep. 2015;5:12642.","journal-title":"Sci Rep"},{"key":"296_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3109\/10799893.2015.1026444","volume":"35","author":"A Jesionowska","year":"2015","unstructured":"Jesionowska A, Cecerska-Heryc E, Matoszka N, Dolegowska B. Lysophosphatidic acid signaling in ovarian cancer. J Recept Signal Transduct Res. 2015;35:578\u201384.","journal-title":"J Recept Signal Transduct Res"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-021-00296-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-021-00296-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-021-00296-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T02:54:57Z","timestamp":1726282497000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-021-00296-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1186\/s11658-021-00296-3","relation":{},"ISSN":["1425-8153","1689-1392"],"issn-type":[{"value":"1425-8153","type":"print"},{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"19 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human or animal experiments were performed.\u00a0Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participant has consented to the submission of this report to your journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"51"}}